Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856206 · ClinicalTrials.gov registry record · Phase 3
Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
A Phase 3 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,315
- Enrollment target
NCT00856206 is a Phase 3 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 1,315 participants.
The verdict
NCT00856206, a Phase 3 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,315 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are on urate-lowering therapy. Subjects will participate in this study for approximately 20 weeks. Rilonacept is being studied for use in preventing gout flares in subjects on urate-lowering therapy.
Interventions
- OTHER Placebo
- BIOLOGICAL Rilonacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,315 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00856206
The ClinicalTrials.gov registry entry for NCT00856206 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00856206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00856206 about?
NCT00856206 is a clinical study titled "Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)". The purpose of this clinical research study is to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are on urate-lowering therapy. Subjects will participate in this study for approximately 20 weeks. Rilonacept is being studied for use in preve...
What is the current status of trial NCT00856206?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,315 participants. The study started on 2009-03. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00856206?
The interventions under investigation include: Placebo (OTHER), Rilonacept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00856206?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.